MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Viatris Inc. (NASDAQ:VTRS), formerly, Mylan NV (MYL)
Organization & Developments: Mylan
Parents
Viatris Inc. (NASDAQ:VTRS), formerly, Mylan NV (MYL)
Children
*Global generic and specialty pharmaceuticals company registered in the Netherlands
*Mylan
*Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world
*Mylan Pharmaceuticals, Morgantown, West Virginia
*Mylan Technologies Inc. (MTI) - transdermal drug delivery systems (TDDS) and related technologies
*Operational headquarters in Hatfield, Hertfordshire in the United Kingdom
*The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer
2016: EpiPen Maker Settles With DOJ for $465 Million
2016: How Mylan cornered the consumer epinephrine market
2016: Think EpiPen is Mylan's first scandal? Here's a timeline of jet use, an unearned MBA and more
2019: Pfizer in talks to merge off-patent drugs business with Mylan: source
2020: Mylan NV is now Viatris with combination with Upjohn
2021: Why Viatris Is Growth At A Reasonable Price
2022: Biosimilars unite: Looking for commercial consolidation, Biocon buys out longtime partner Viatris for $3.3B
2022: Viatris Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Viatris: 5% Dividend Yield Is A Threat For Investors_seekingalpha.com
2022: Viatris: A Spinoff That Got Even More Interesting_ seekingalpha.com
2023: Viatris Stock Is Dirt Cheap And Worth Buying_ seekingalpha.com
2023: Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss
2023: Viatris' Survival Guide: Strategic Divestitures And Margins
2024: From Euphoria To Reality: Viatris' Tale Of Market Whirlwind_seekingalpha.com
2024: Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued
2024: Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma_ seekingalpha.com
2024: Viatris Reduces Debt But Faces Growth Hurdles
2024: Viatris says India plant hit with FDA warning letter, import ban on 11 products
2024: Viatris Stock Is Still Worth Buying
2024: Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential
2024: Why Bargain-Priced Viatris Could Deliver Strong Returns
2025: Viatris: A Unique S&P 500 'Fallen Angel' With Intriguing Potential
2025: Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
2026: Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS) | Seeking Alpha
Jumps
*Key People: Mylan
Finance & Acquisitions: Mylan